Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378

Benzinga · 2d ago
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.